t(4;11) (q21;q23) in acute myeloid leukemia-M0 following treatment [EW92 Protocol] for Ewing's sarcoma

Revista Brasileira de Hematologia e Hemoterapia

Terezinha J. Marques Salles²  Márcia B. Costa²  Vera L. L. Morais²  Romualdo J. Filho²  Mario H. Magalhães²  Maria L. M. Silva¹  Sandra M. A. Silva²  Maria S. Pombo De Oliveira¹ 

[1] ,Hospital Universitário Oswaldo Cruz Serviço de Anatomia Patológica Centro de Oncologia PediátricaRecife Pernambuco

关键词: Therapy-related acute myeloid leukemia;    MLL gene;    Ewing's sarcoma;    Topoisomerase II inhibitors;    G-CSF;    Leucemia mielóide aguda secundaária;    translocação envolvendo a região 11q23 após uso de etoposídio;   

DOI  :  10.1590/S1516-84842004000200010

来源: SciELO

【 摘 要 】

We report on a 7-year-old girl with Ewing's Sarcoma (ES) who developed a poorly differentiated acute myeloid leukemia (AML-M0) 20 months after beginning the EW92 protocol for the treatment of the primary tumor. She received a total dose of 1500 mg of etoposide, a tumor cumulative radiation dose of 35Gy and granulocyte colony-stimulating factor (G-CSF) was as predicted in the protocol regimen. At onset of secondary malignancy her laboratorial analysis revealed immature blast cells characterized by CD34+/CD33-/a-MPO+ and a t(4;11)(q21;q23) abnormality. This serious complication of ES treatment, which associates etoposide, irradiation and G-CSF schedule, should be weighed against its therapeutic benefits.

【 授权许可】

CC BY-NC-ND   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License